attention deficit hyperactivity disorder. Disturbance of activity and attention
Conditions
Interventions
Intervention 1: intervention group: vitamin D, 2000IU, one tablet daily for 8 weeks. Intervention 2: control group: placebo containing starch and lactose, one tablet daily for 8 weeks.
Treatment - Drugs
intervention group: vitamin D, 2000IU, one tablet daily for 8 weeks
control group: placebo containing starch and lactose, one tablet daily for 8 weeks
Sponsors
Vice Chancellor for Research, Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
6 Years to 12 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Signed parental (mother/father) informed consent; 6-12 years old children; Newly diagnosed attention deficit hyperactivity disorder children by child and adolescent psychiatrist; BMI percentile between 5 to 85. Exclusion criteria: History or current diagnosis of other psychiatric diseases (e.g., autism, bipolar disorder, major depression disorder, etc.) by psychiatrist; History or current diagnosis of neurological condition (e.g., epilepsy, brain tumors, etc.) by psychiatrist; History or current diagnosis of any serious systemic (e.g., diabetes, hyper/hypothyroidism, etc.); History of major head trauma ; Diagnosis of Mental retardation; Any medicine administration at least 4weeks before the initiation of the study; Any vitamin D products (enriched products with vitamin D) at least 3 months before the initiation of the study; Any supplement use containing antioxidants like multivitamin, vitamin A,C,E at least 2 months before the initiation of the study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Symptoms of disease. Timepoint: week 0,4 and 8. Method of measurement: Parental Conners questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Symptoms in morning and evening. Timepoint: week 0,4 , 8. Method of measurement: Morning-evening symptoms questionnaire.;Adverse drug effects. Timepoint: week 4,8. Method of measurement: Adverse drug effects questionnaire.;Serum level of Malondialdehyde. Timepoint: week 0,8. Method of measurement: blood test.;Serum level of 8-hydroxydeoxyguanosine. Timepoint: week 0,8. Method of measurement: blood test.;Serum level of 25-hydroxyD. Timepoint: week 0,8. Method of measurement: blood test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNakisa Mohammadpour
Nutrition and dietetics faculty of Tehran university of medical sciences
Outcome results
None listed